The Importance of Tracking “Missing” Metabolites: How and Why?-Reference-Cited by-同舟云学术

The Importance of Tracking “Missing” Metabolites: How and Why?

Published:2023-09-28 Issue:23 Volume:66 Page:15586-15612
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wang Shuai¹^ORCID,Ballard T. Eric²,Christopher Lisa J.³,Foti Robert S.⁴,Gu Chungang⁵,Khojasteh S. Cyrus¹,Liu Joyce¹,Ma Shuguang⁶,Ma Bin¹^ORCID,Obach R. Scott⁷,Schadt Simone⁸^ORCID,Zhang Zhoupeng⁹,Zhang Donglu¹^ORCID

Affiliation:

1. Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States

2. Takeda Development Center Americas, Inc., 35 Landsdowne St, Cambridge, Massachusetts 02139, United States

3. Department of Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States

4. Preclinical Development, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States

5. Drug Metabolism and Pharmacokinetics, Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142, United States

6. Drug Metabolism and Pharmacokinetics, Pliant Therapeutics, 260 Littlefield Avenue, South San Francisco, California 94080, United States

7. Pharmacokinetics, Dynamics, and Metabolism, Pfizer, Inc., Eastern Point Road, Groton, Connecticut 06340, United States

8. Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Strasse 124, 4070 Basel, Switzerland

9. DMPK Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01293

Reference181 articles.

1. Food and Drug Administration. Safety Testing of Drug Metabolites - Guidance for Industry, November 2016 (updated March 5, 2020). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-testing-drug-metabolites.

2. International Council for Harmonisation. ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals, 2009. https://www.ema.europa.eu/en/ich-m3-r2-non-clinical-safety-studies-conduct-human-clinical-trials-pharmaceuticals-scientific.

3. Food and Drug Administration. Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies - Guidance for Industry, May 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-human-radiolabeled-mass-balance-studies.

4. Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection

5. Metabolism-guided drug design

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioactivation and reactivity research advances – 2023 year in review;Drug Metabolism Reviews;2024-07-17

2. Biotransformation research advances – 2023 year in review;Drug Metabolism Reviews;2024-07-11

3. Metabolism of new drug modalities research advances – 2023 year in review;Drug Metabolism Reviews;2024-07-05

4. Alpibectir: Early Qualitative and Quantitative Metabolic Profiling from a First-Time-in-Human Study by Combining¹⁹F-NMR (Nuclear Magnetic Resonance),¹H-NMR, and High-Resolution Mass Spectrometric Analyses;Drug Metabolism and Disposition;2024-05-20

5. Small molecule drug metabolite synthesis and identification: why, when and how?;Drug Discovery Today;2024-05